A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

Abstract Background The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer...

Full description

Bibliographic Details
Main Authors: Yaxin Liu, Wei Wang, Rutie Yin, Youzhong Zhang, Yu Zhang, Keqiang Zhang, Hongming Pan, Ke Wang, Ge Lou, Guiling Li, Ruyan Zhang, Kun Li, Jing Rao, Ben Zhang, Yuting Wang, Quanren Wang, Yunong Gao, Huiping Li
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Medicine
Subjects:
Ovarian cancer
Triple-negative breast cancer
PARP inhibitor
Anti-angiogenic therapy
gBRCA
Online Access:https://doi.org/10.1186/s12916-023-03046-8

Internet

https://doi.org/10.1186/s12916-023-03046-8

Similar Items